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ABSTRACT
Herkinorin is the first -opioid receptor-selective ligand from
the salvinorin A diterpenoid scaffold. Herkinorin has relative
     binding selectivity, and it can act as an agonist at
both - and -receptors, in vitro. These studies were the first
in vivo evaluation of the effects of herkinorin in nonhuman
primates, using prolactin release, a neuroendocrine biomarker
assay that is responsive to both - and -agonists, as well as
to compounds with limited ability to cross the blood-brain
barrier. In cumulative dosing studies (0.01–0.32 mg/kg i.v.),
herkinorin produced only small effects in gonadally intact males
(n 4), but a more robust effect in females (n 4). Time course
studies with herkinorin (0.32 mg/kg) confirmed this greater
effectiveness in females and revealed a fast onset after i.v.
administration (e.g., by 5–15 min). Antagonism experiments
with different doses of nalmefene (0.01 and 0.1 mg/kg) caused
dose-dependent and complete prevention of the effect of herki-
norin in females. This is consistent with a principal -agonist
effect of herkinorin, with likely partial contribution by -agonist
effects. The peripherally selective antagonist quaternary nal-
trexone (1 mg/kg s.c.) caused approximately 70% reduction in
the peak effect of herkinorin (0.32 mg/kg) in females, indicating
that this effect of herkinorin is prominently mediated outside the
blood-brain barrier.
Salvinorin A, a plant-derived hallucinogenic diterpene, is a
highly selective -opioid agonist, and a novel template for
semisynthetic opioid analogs (Roth et al., 2002; Prisinzano
and Rothman, 2008). One of these novel analogs is herki-
norin, the first salvinorin-derived compound with - over
-selectivity reported in the literature (Harding et al., 2005).
Herkinorin has approximately 8-fold selectivity for - over
-receptors and approximately 98-fold selectivity for - over
-receptors in competition binding assays (Harding et al.,
2005). Herkinorin acts as a high-efficacy agonist at both -
and -receptors in the guanosine 5-O-(3-thio)triphosphate
assay (Harding et al., 2005), with greater relative potency at
-receptors. Herkinorin also displays some unique features
in its interactions at the -receptor, such as decreased ago-
nist-induced internalization (Groer et al., 2007; Xu et al.,
2007).
To date, there is no information on the in vivo effects of
herkinorin in primates. The present study focuses on an
initial evaluation of the in vivo opioid agonist effects of
herkinorin in rhesus monkeys, using a translationally vi-
able neuroendocrine biomarker assay, release of the ante-
rior pituitary hormone prolactin. Different factors render
this neuroendocrine biomarker a practical approach for
initial evaluation of herkinorin: 1) prolactin levels are
increased by both - and -agonists in mammals, including
humans (-agonists seem not be to be active) (Hoehe et al.,
1988; Ur et al., 1997; Kreek et al., 1999; Bowen et al., 2002;
Butelman et al., 2007); and 2) effects of these opioids are at
least partially mediated by opioid receptors outside the
blood-brain barrier (e.g., in particular hypothalamic nuclei)
(Merchenthaler, 1991; Butelman et al., 2004, 2008; Zheng et
al., 2005), and they may therefore be used to determine the
pharmacodynamic effects of compounds with limited ability
to cross the blood-brain barrier.
This study presents the first direct evaluation of the phar-
macodynamic effects of herkinorin in male and female non-
human primates, and it also investigates potential -versus
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-receptor effects of this novel compound, as well as activity
outside the blood-brain barrier.
Materials and Methods
Subjects
Four captive-bred male and four female rhesus monkeys (Macaca
mulatta; age range, approximately 8–12 years; weight range, 7.0–
12.5 kg) were used. All subjects were gonadally intact. Unless oth-
erwise stated, each study was carried out with an n  4 of either
males or females. Females were studied in the follicular phase,
estimated as days 1 to 12 from the onset of visible menses. Monkeys
were singly housed in colony rooms maintained at 20 to 22°C, with
controlled humidity and a 12:12-h light/dark cycle (lights on at 7:00
AM). Monkeys were fed approximately 12 jumbo primate chow bis-
cuits, adjusted individually (PMI Feeds, Richmond, VA). Subjects
also received appetitive treats, and multivitamins plus iron. An
environmental enrichment plan was in place (e.g., music and videos).
Water was freely available in home cages, via a waterspout.
Subjects had complex history of pharmacological exposure (pri-
marily opioid), but they had no history of any chronic or high-
frequency exposure to any agent. Consecutive experiments in the
same subject were separated by at least 72 h; the order of experi-
ments was unsystematic among subjects. All studies were carried
out over the course of several months while all subjects were in
stable colony rooms. Studies were reviewed by the Rockefeller Uni-
versity Animal Care and Use Committee, in accordance with the
Guide for the Care and Use of Animals (National Academies Press;
Washington, DC, 1996).
Procedure for Neuroendocrine Experiments
Chair-trained monkeys were tested after repeated exposure to the
experimental situation. Monkeys were chaired and transferred to
the experimental room between 9:45 AM and 10:30 AM each test
day, approximately. An indwelling catheter (24-gauge, Angiocath;
BD Medical Systems-Infusion Therapy, Sandy, UT) was placed in a
superficial leg vein and secured with elastic tape. An injection port
(Terumo Medical Corporation, Elkton, MD) was attached to the
catheter; port and catheter were flushed (0.3 ml of 50 U/ml heparin-
ized saline) before use and after blood sampling or injection. Approx-
imately 20 min after catheter placement, two baseline blood samples
of approximately 1.5 ml were collected, 5 min apart from each other
(defined as 10 and 5 min, relative to the onset of drug injection).
Samples were kept at room temperature until the time of spinning
(3000 rpm at 4°C) and serum separation. Serum samples were kept
at 40°C until time of analysis (typically within 2 weeks of collec-
tion). Samples were analyzed in duplicate with a standard human
prolactin immunoradiometric kit (DPC-Siemens Medical Solutions
Diagnostics, Los Angeles, CA), following manufacturer’s instruc-
tions. Studies report high protein homology in human versus rhesus
monkey prolactin, as well as antibody cross-reactivity (Brown and
Bethea, 1994; Pecins-Thompson et al., 1996). The reported sensitiv-
ity limit of this assay was 0.1 ng/ml; each individual kit was cali-
brated with known standards, in the range 2 to 200 ng/ml. The intra-
and interassay coefficients of variation with this kit in the laboratory
were approximately 3 and 11%, respectively.
Cumulative Dosing Procedure. Monkeys were tested in a cu-
mulative dosing or time course procedure. A cumulative dosing pro-
cedure was used to produce a rapid initial estimate of the potency
and effectiveness of herkinorin within a single session. Cumulative
dosing procedures have been used previously to efficiently measure
potency and effectiveness of - and -agonists in this biomarker
assay (Bowen et al., 2002; Butelman et al., 2002). Cumulative dosing
studies commenced with baseline preinjection sample collection (two
separate samples taken approximately 10 and 5 min before the onset
of dosing), followed by four consecutive 30-min interinjection cycles,
with agonist doses increasing in 0.5 log unit steps. Blood sampling
occurred 15 min after each injection. Herkinorin was studied herein
up to the largest dose that could be administered due to solubility
limitations (0.32 mg/kg). Herkinorin was then compared with salvi-
norin A (its structurally related parent compound, a selective -ag-
onist) and loperamide (a peripherally selective -agonist), under
similar conditions. A vehicle control study was also carried out, with
four consecutive vehicle injections under identical timing conditions.
Time Course Procedure. After baseline sample collection, a
single agonist dose (e.g., of herkinorin) was administered i.v., fol-
lowed by sampling at 5, 15, 30, 60, 90, and 120 min after adminis-
tration. In antagonism experiments, a single dose of antagonist (s.c.
nalmefene or quaternary naltrexone) was administered 30 min be-
fore an agonist, followed by testing as described above. In these
antagonism experiments, a single sample was also taken 20 min
after administration of the antagonist alone (i.e., during the pre-
treatment period).
Design
Cumulative Dose-Effect Curve Studies. Cumulative dose-ef-
fect curve studies were carried out in males and females for herki-
norin (0.01–0.32 mg/kg i.v.) compared with repeated vehicle injec-
tion, for control purposes. The effects of loperamide [0.01–0.32 mg/kg
(males and females)] and salvinorin A [0.001–0.032 mg/kg (males)
and 0.00032–0.01 mg/kg (females), based on prior studies; Butelman
et al., 2007, 2008] were also studied under identical cumulative
dosing procedures.
Time Course Studies. The time course effects of herkinorin were
studied in male subjects, at the largest dose that could be adminis-
tered, as limited by solubility (0.32 mg/kg i.v., compared with vehicle
i.v.). This was followed by a similar determination of the effects of
this dose in females.
Because males demonstrated only a small effect of herkinorin up
to the largest dose that could be studied, antagonism experiments
described below were only carried out in females. Nalmefene (0.01 or
0.1 mg/kg s.c.) was thus administered as a pretreatment to herki-
norin (0.32 mg/kg i.v.). Nalmefene has relative - over -selectivity
as an antagonist in primates (France and Gerak, 1994). In prior
studies, the lower nalmefene dose (0.01 mg/kg) was sufficient to
block the effects of selective -agonists (France and Gerak, 1994),
whereas the larger dose (0.1 mg/kg) was necessary to block the
effects of -agonists (Butelman et al., 2007). The effects of herkinorin
(0.32 mg/kg) were also studied after pretreatment with the periph-
erally selective antagonist quaternary naltrexone (1 mg/kg s.c.) (Val-
entino et al., 1983). In a comparison study, the effects of fentanyl
(0.01 mg/kg i.v.) were studied after analogous pretreatment with a
-selective dose of nalmefene (0.01 mg/kg).
Neuroendocrine Data Analysis
Raw individual prolactin values for each experiment were con-
verted to change in prolactin levels from individual preinjection
baseline (i.e., nanograms per milliliter) by subtracting mean pre-
injection baseline value for each subject. Data were then analyzed
with two-way repeated measures analysis of variances (ANOVAs)
(e.g., time 	 drug condition) using SigmaStat 3.1 (Systat Software,
Inc., San Jose, CA), followed by Newman-Keuls post hoc testing.
Values are presented to two decimal places, and the level of signifi-
cance (
) for all comparisons was set at 0.05.
Drugs
Herkinorin was synthesized in the laboratory of Dr. Thomas E.
Prisinzano (Harding et al., 2005), and it was dissolved daily in 10%
dimethyl sulfoxide/10% Tween 80/sterile water (v/v). Salvinorin A
(extracted from commercially obtained leaves from Ethnogens.com
in Dr. Prisinzano’s laboratory) and loperamide HCl (Sigma-Aldrich,
St. Louis, MO) were dissolved in 10% ethanol/10% Tween 80/80%
sterile water (v/v). Quaternary naltrexone methobromide (also
known as methylnaltrexone) was kindly supplied by Dr. Chun-Su
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Yuan (Department of Anesthesiology, University of Chicago, Chi-
cago, IL), and it was dissolved daily in sterile water. Nalmefene HCl
(Baker-Norton, Miami, FL) was dissolved in sterile water. Drug
doses are reported in the forms stated above. All drugs were injected
in volumes of 0.05 to 0.3 ml/kg.
Results
Cumulative Dosing: Baseline and Vehicle Control
Experiment
Mean baseline prolactin levels in a cumulative vehicle
experiment were 6.8 ng/ml (S.E.M. 2.3) in males and 18.8
ng/ml (S.E.M. 6.1) in females. Four consecutive vehicle injec-
tions (30-min interinjection interval; sampling 15 min after
injection) resulted in small decreases in prolactin levels. For
example, after the fourth injection, mean prolactin values
were 2.6 ng/ml (S.E.M. 1.4) in males and 3.3 ng/ml
(S.E.M. 9.9) in females. Mean nanograms per milliliter val-
ues over four consecutive cycles with vehicle administration
are presented in Fig. 1.
Cumulative Dosing Studies
Herkinorin. Up to the largest dose that could be studied
(0.32 mg/kg), herkinorin only caused a small increase in
prolactin levels in males [mean 14.4 ng/ml (S.E.M. 7.7)].
However, in females, a greater maximal effect was detected
at the largest dose [mean 175.8 ng/ml (S.E.M. 47.4)] (Fig. 1).
See below for statistical analysis of these cumulative dose-
effect curve data.
Salvinorin A. In a comparative study, salvinorin A was
studied in a similar cumulative dosing procedure in males
versus females. Dose ranges were adjusted based on prior
information of the greater effectiveness of a salvinorin A dose
in males versus females (Butelman et al., 2007). Salvinorin A
(0.001–0.032 mg/kg) caused robust dose-dependent effects in
males [maximal mean 135.7 ng/ml (S.E.M. 29.4), at 0.032
mg/kg]. Salvinorin A (0.00032–0.01 mg/kg) caused even more
robust effect in females [maximal mean 314.9 ng/ml (S.E.M.
90.6), at 0.01 mg/kg] (Fig. 1). See below for statistical anal-
ysis of these cumulative dose-effect curve data.
Loperamide. Loperamide caused dose-dependent prolac-
tin increases in males [103 ng/ml (S.E.M. 48.4), at 0.32
mg/kg]. Loperamide also caused robust, dose-dependent pro-
lactin increases in females [maximal mean 202.1 ng/ml
(S.E.M. 23.7), at 0.32 mg/kg)] (Fig. 1). See below for statisti-
cal analysis of these cumulative dose-effect curve data.
Analysis of Dose-Effect Curve Data for All Com-
pounds. For males and females, two-way repeated measures
ANOVAs were carried out for drug (vehicle, herkinorin, salvi-
norin A, or loperamide) versus dose (as used in this four-cycle
procedure), using nanogram per milliliter values (i.e., after
subtraction of individual preinjection baseline). The aim of
this analysis was to describe the observed effects in the
dose-effect curve studies, while taking into account individ-
ual baseline differences, and the slight decrease that is ob-
served through repeated vehicle administration in this set-
ting (see above).
In males, this drug	 dose ANOVA resulted in main effects
of drug [F(3,9)  9.94; p  0.003], dose [F(3,9)  9.89; p 
0.003], and their interaction [F(9,27)  6.23; p  0.001].
Herkinorin was not different from its cycle-matched vehicle
control, in any of the doses tested. Salvinorin A was signifi-
cantly different from vehicle at the two largest doses studied
(0.01 and 0.032 mg/kg; q  5.60 and 10.08, respectively; all
p  0.05). Loperamide was significantly different from vehi-
cle only at largest dose studied (0.32 mg/kg; q  7.70; p 
0.05).
In females, the drug 	 dose ANOVA also resulted in main
effects of drug [F(3,9) 8.58; p 0.005], dose [F(3,9) 22.02;
p  0.001], and their interaction [F(9,27)  7.74; p  0.001].
Herkinorin was significantly different from vehicle at the
largest dose studied (0.32 mg/kg; q  7.18; p  0.05). Salvi-
norin A was significantly different from vehicle at the two
largest doses studied (0.0032 and 0.01 mg; q  4.61 and
12.76, respectively; all p  0.05). Loperamide was different
from vehicle only at the largest dose studied (0.32 mg/kg; q 
8.24; p  0.05).
Time Course Studies
Baseline and Vehicle Control Experiment. In the ve-
hicle control time course experiment, males exhibited mean
baseline preinjection prolactin values of 8.7 ng/ml (S.E.M.
1.1). Females had similar mean preinjection values 8.3 ng/ml
(S.E.M. 1.9). Bolus administration of the vehicle used in
herkinorin studies [1:1:8 dimethyl sulfoxide/Tween 80/sterile
water (v/v)] resulted in slight gradual decreases in prolactin
levels over the course of the experiment, reaching 4 ng/ml
(S.E.M. 1) for males and 3.2 ng/ml (S.E.M. 0.6) for fe-
males, at the last (120 min) time point (Fig. 2).
Time Course Effects of Herkinorin. Up to the largest
dose that could be administered (0.32 mg/kg i.v.), herkinorin
caused a modest but significant time-dependent increase in
serum prolactin levels in males (peak mean levels of 19.1
ng/ml [S.E.M. 7.3]) (Fig. 2; note ordinate axis break). A
rapid onset was observed in this effect, with peak effects
observed at the earliest sample point (5 min after adminis-
tration). A two-way repeated measures ANOVA [condition
(vehicle or herkinorin) versus postinjection time] revealed a
main effect of condition [F(1,3)  12.2; p  0.04], time
[F(5,15)  6.0; p  0.003], and their interaction [F(5,15) 
4.0; p  0.02]. A Newman-Keuls test confirmed that herki-
norin caused an increase in prolactin levels compared with
vehicle at 5, 15, and 30 min after administration (q  5.73,
5.41, and 5.0, respectively; all p  0.05), but not at later time
points (i.e., 60–120 min).
By contrast, the same herkinorin dose in females caused a
greater maximal effect 5 min after administration [peak
maximum 306.6 ng/ml (S.E.M. 91)] (note ordinate axis
break in Fig. 2). A two-way repeated measures ANOVA [con-
dition (vehicle or herkinorin) versus post injection time] re-
vealed a main effect of condition [F(1,3)  15.34; p  0.03],
Fig. 1. Chemical structures of the parent compound salvinorin A (left)
and its -selective analog herkinorin (right).
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time [F(5,15)  10.74; p  0.001], and their interaction
[F(5,15) 10.48; p 0.001]. A Newman-Keuls test confirmed
that herkinorin caused an increase in prolactin levels com-
pared with vehicle at 5, 15, and 30 min after administration
(q  9.56, 6.55, and 4.03, respectively; all p  0.05), but not
at later time points (i.e., 60–120 min).
Antagonism Experiments. Due to the small magnitude
of the effect of herkinorin in males, subsequent antagonism
experiments were only carried out in females, against the
herkinorin 0.32-mg/kg dose. Nalmefene was administered in
two separate pretreatment experiments (0.01 or 0.1 mg/kg).
In either case, nalmefene alone (measured 20 min after
administration) did not cause a change in prolactin levels
(data not shown). Nalmefene, at two pretreatment doses
(0.01 and 0.1 mg/kg), produced a partial and complete block-
ade of the effect of herkinorin, respectively. A two-way re-
peated measures ANOVA [condition (vehicle alone, herki-
norin alone, and herkinorin after nalmefene 0.01 or 0.01
mg/kg pretreatment) 	 postinjection time] revealed a signif-
icant main effect of condition [F(3,9)  11.98; p  0.002],
postinjection time [F(5,15)  10.48; p  0.001], and their
interaction [F(15,45)  8.16; p  0.001] (Fig. 3, left).
Newman-Keuls tests revealed that there was a significant
effect of nalmefene (0.01 mg/kg) pretreatment versus herki-
norin alone at 5, 15, and 30 min after administration (q 
9.38, 5.95, and 3.94, respectively; all p  0.05). The larger
nalmefene pretreatment dose (0.1 mg/kg) also caused a sig-
nificant difference versus herkinorin alone at 5, 15, and 30
min (q  12.51, 8.61, and 5.37, respectively; all p  0.05).
In a comparison experiment, the -selective agonist fent-
anyl (0.01 mg/kg) produced prolactin-releasing effects of a
similar magnitude to those of herkinorin, but it was fully
blocked by the smaller dose of nalmefene (0.01 mg/kg) (Fig. 3,
right). A two-way repeated measures ANOVA [condition (ve-
hicle alone, fentanyl alone, fentanyl after nalmefene 0.01
mg/kg pretreatment) 	 postinjection time] revealed a sig-
nificant main effect of postinjection time [F(5,15)  3.89;
p  0.02] and condition 	 postinjection time interaction
[F(10,30)  3.06; p  0.009]. Newman-Keuls tests revealed
that nalmefene (0.01 mg/kg) pretreatment resulted in signif-
icant differences versus fentanyl alone at 5 and 15 min (q 
3.87 and 5.68; all p  0.05).
The effects of herkinorin (0.32 mg/kg) were also studied
after pretreatment with the peripherally selective antag-
onist quaternary naltrexone (1 mg/kg). Quaternary nal-
trexone alone did not have an effect on prolactin levels (20
min after administration; data not shown). Quaternary
naltrexone caused a partial reduction in herkinorin’s effect
(Fig. 4). A two-way repeated measures ANOVA [condition
(herkinorin alone versus herkinorin after quaternary nal-
trexone pretreatment) 	 postinjection time] revealed a
significant main effect of postinjection time [F(5,15) 
8.13; p  0.001] and condition 	 postinjection time inter-
action [F(5,15)  5.87; p  0.003]. Newman-Keuls compar-
isons confirmed that quaternary naltrexone pretreatment
caused a blockade in the effect of herkinorin at 5 and 15
min (q  6.89 and 4.0, respectively; all p  0.05) (Fig. 5).
Larger quaternary naltrexone doses were not probed
herein due to supply limitations.
Discussion
Herkinorin is the first compound derived from the salvi-
norin A diterpenoid scaffold to have - over -selectivity
(Harding et al., 2005). The present neuroendocrine biomar-
ker assay (prolactin release) is responsive to both - and
-agonists in humans and nonhuman primates and humans;
therefore, it is a translationally viable assay to study the in
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Fig. 2. Cumulative dose-effect curves for i.v. salvinorin A, loperamide,
and herkinorin in gonadally intact males and females (top and bottom,
respectively). Abscissae, cumulative dose in milligrams per kilogram.
Ordinates, effects on prolactin levels compared with individual preinjec-
tion baseline (nanograms per milliliter;  S.E.M.). Dashed line is the
mean value for repeated vehicle injection in these subjects (four consec-
utive dosing cycles, with a 30-min interinjection interval). , significantly
different from cycle-matched vehicle control, p 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ide and herkinorin were significantly different from cycle-matched vehi-
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 0.05. See text for details.
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from bolus i.v. injection (minutes). Ordinate, effects on prolactin levels
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ter;  S.E.M.). Please note break in ordinate axis, to illustrate difference
between effects in males versus females. , significantly different from
respective vehicle time point. See text for details.
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vivo pharmacology of this novel compound (Hoehe et al.,
1988; Bart et al., 2003).
In cumulative dosing studies in males (0.01–0.32 mg/kg
i.v.), herkinorin only caused a small, and nonstatistically
significant effect, up to the largest dose that could be studied
under the present solubility conditions. For comparison, the
parent compound salvinorin A displayed greater potency and
efficacy than herkinorin in males. The peripherally selective
-agonist loperamide also displayed greater effectiveness
than herkinorin in males.
The effect of herkinorin in females was more robust. The
parent compound salvinorin A was approximately 30-fold
more potent than herkinorin in females. The peripherally
selective -agonist loperamide was approximately equi-
potent and equieffective to herkinorin in this determination
in females.
The relative ineffectiveness of herkinorin in males could be
potentially interpreted as a sign of partial agonist effects in
this assay, compared with loperamide and salvinorin A (both
of these latter ligands have high efficacy and selectivity at
their respective receptor targets, the - and -receptors, re-
spectively) (DeHaven-Hudkins et al., 1999; Roth et al., 2002).
However, herkinorin also has relatively high efficacy at both
- and -receptors in vitro (with greater relative potency at 
over ) (Harding et al., 2005). Furthermore, recent unpub-
lished pilot studies with herkinorin (0.32 mg/kg) as a pre-
treatment to either salvinorin A (0.032 mg/kg) or loperamide
(0.32 mg/kg) were not consistent with partial agonist effects
by herkinorin (i.e., no herkinorin-induced blockade of salvi-
norin A or loperamide was observed). Thus, based on these
findings, it is more likely that the present lack of herkinorin
effectiveness in males is due to practical limits to reach a
sufficiently high dose in vivo, as limited by solubility.
To further investigate the agonist effects of herkinorin,
time course studies at the largest herkinorin dose were car-
ried out (0.32 mg/kg, measured 5–120 min after i.v. bolus).
These findings were generally consistent with the cumula-
tive dose-effect curve study. In the time course studies, a
small but significant effect was observed in males, whereas a
robust effect was observed in females. Herkinorin displayed a
fast onset after i.v. administration (peak values were ob-
served at 5–15 min). Intriguingly, although the effectiveness
of herkinorin was greater in females than in males, the
duration of action of herkinorin was similar in subjects of
either sex. Specifically, herkinorin was significantly different
from vehicle only up to 30 min after administration in either
females or males. These are the first studies to compare the
effects of herkinorin in male and female subjects of any
species, to our knowledge. Similarly to the parent compound
salvinorin A, herkinorin displayed robustly increased effec-
tiveness in females versus males. These studies are consis-
tent with research in humans, showing that opioid agonists
can cause more robust effects on this neuroendocrine end-
point in females than in males (Kreek et al., 1999).
The demonstration that a compound can cause prolactin
release is not sufficient to implicate opioid receptors, because
several types of compounds in addition to opioids also have
this effect (including dopaminergic antagonists or serotoner-
gic agonists; see, e.g., Aloi et al., 1984; Nordstro¨m and Farde,
1998). Consequently, antagonism studies were designed to
determine whether opioid (- and or -receptor) mechanisms
were involved in the effects of herkinorin. Antagonism stud-
ies such as apparent pA2 or pKB analyses were not under-
taken herein, because the solubility of herkinorin under
these conditions precluded investigation of surmountability.
In addition, antagonism studies were only undertaken in
females, due to the small magnitude of the observed effect of
herkinorin in males.
Nalmefene has a relative - over -selectivity as an antag-
onist in nonhuman primates (France and Gerak, 1994; Butel-
man et al., 2002), and it does not in itself cause prolactin
release in nonhuman primates (as found in the present study
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Fig. 4. Antagonism of the effects of herki-
norin (0.32 mg/kg) in females by nalmefene
(0.01 or 0.1 mg/kg) or of fentanyl (0.01 mg/kg)
by nalmefene (0.01 mg/kg; right). Nalmefene
alone, measured 20 min after administration,
had no effect on prolactin levels (data not
shown). See Fig. 2 for other details. #, either
dose of nalmefene was significantly different
from herkinorin alone, p  0.05. See text for
details.
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Fig. 5. Antagonism of the effects of herkinorin (0.32 mg/kg) in females by
quaternary naltrexone (1 mg/kg s.c.). Quaternary naltrexone alone, mea-
sured 20 min after administration, had not effect on prolactin levels (data
not shown). , significantly different from herkinorin alone, p  0.05. See
Fig. 2 and text for details.
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and Butelman et al., 1999; Mello et al., 2000). It is interesting
to note that nalmefene exhibits partial -agonist effects in
cloned human -receptors in the guanosine 5-O-(3-thio)-
triphosphate assay, and it does cause detectable prolactin
release in humans (Bart et al., 2005). In the present study,
0.01 mg/kg nalmefene produced a partial reduction (by ap-
proximately 75%, from a mean peak of 306.6 to 79.8 ng/ml)
in the effects of herkinorin in females. The larger dose of
nalmefene (0.1 mg/kg) was able to produce essentially com-
plete blockade of this effect (by approximately 98%, to a mean
peak of 4.4 ng/ml). Given prior data on doses of nalmefene
active against - and -opioid ligands in rhesus monkeys
(France and Gerak, 1994; Butelman et al., 2002, 2007), this
suggests that the effects of herkinorin are mediated princi-
pally by -receptors and that -receptors may also be par-
tially involved. These data are consistent with the in vitro
profile of herkinorin, which shows relative (approximately
8-fold) binding selectivity for - over -receptors (Harding et
al., 2005). As a direct confirmation in this setting, the smaller
dose of nalmefene (0.01 mg/kg) was indeed sufficient to cause
complete blockade of the effects of the selective -agonist
fentanyl (also see Butelman et al., 2008). This confirms that
an agonist thought to act solely through -receptors in this
assay is fully blocked by the smaller nalmefene dose under
these experimental conditions. Antagonism experiments with
more selective -opioid antagonists (e.g., norbinaltorphimine)
were not undertaken due to the potential for ultralong duration
of such antagonists on neuroendocrine endpoints (at least sev-
eral weeks) (Pascoe et al., 2008).
As recently shown and confirmed herein (e.g., with loper-
amide), -receptors located outside the blood-brain barrier
(probably in the hypothalamus) can mediate prolactin-releas-
ing effects in primates (Merchenthaler, 1991; Zheng et al.,
2005; Butelman et al., 2008). For comparison, we recently
reported that fentanyl may produce this effect by acting on
-receptor populations inside as well as outside the blood-
brain barrier (Butelman et al., 2008). In this study, the
peripherally selective opioid antagonist quaternary naltrex-
one (methylnaltrexone; 1 mg/kg) (Valentino et al., 1983;
Yuan et al., 2002) caused a partial blockade of the peak effect
of herkinorin (by approximately 70%, to a mean peak of 88.3
ng/ml). This confirms that herkinorin may cause the
present effect by acting at least partially on opioid receptors
outside the blood-brain barrier (Zheng et al., 2005). Based on
prior studies (Butelman et al., 2004) and recent pilot data, we
have also found that quaternary naltrexone is not able to
fully block the effects of -agonists in this endpoint. Thus, it
may not be excluded that the part of the effect of herkinorin
that was insensitive to quaternary naltrexone may have been
mediated by -receptors, rather than by central -receptors
(Butelman et al., 2008). Such a conclusion would in fact be
consistent with the present nalmefene antagonism data (see
above).
To our knowledge, this is the first direct dose-effect curve
comparison of prolactin-releasing effects of - and -opioids
in gonadally intact male and female primates. The present
study confirms that -opioids (e.g., salvinorin A) cause pro-
lactin-releasing effects of both greater potency and greater
apparent efficacy in females than in males (Kreek et al.,
1999). Sex differences for a peripherally selective -opioid
(loperamide) were more modest, and observable mostly as a
difference in maximal effect. Overall, the present dose-effect
curve determinations support the use of this translationally
viable neuroendocrine biomarker for the study of novel -
and -opioid analogs in primates. These findings support use
of the biomarker in human clinical populations, as a means
to determine responsiveness of either - or -receptor pools,
and their association to disease status.
This is also the first evaluation of herkinorin, the first
-selective ligand from the salvinorin scaffold (Harding et al.,
2005), in nonhuman primates, and the first evaluation of its
neuroendocrine effects in any species. This study shows that
herkinorin exhibits moderate potency in vivo and that its
effectiveness in this neuroendocrine biomarker is greater in
females than in males. Antagonism studies confirm that
herkinorin can produce -agonist effects in vivo, although it
may have moderate - over -selectivity in this respect. Last,
studies with quaternary naltrexone suggest that herkinorin
may produce these effects by acting at least partially on
opioid receptors located outside the blood-brain barrier. Ad-
ditional studies to improve the pharmacokinetic properties
and -selectivity of the herkinorin template are ongoing.
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